Barinthus Bio Reports Q2 Loss, Nasdaq Delisting Extension, and Merger Progress
BRNS sits 15% above its 52-week low of $0.512 on light trading volume (0.1× avg).
Summary
Barinthus Bio's Q2 2026 filing shows sharply lower losses, a Nasdaq delisting extension, and progress toward its merger with Clywedog.
Key Events · Earnings and Guidance · BRNS
-
Nasdaq Delisting Extension
Nasdaq granted an additional 180 days, until December 28, 2026, to regain compliance with the $1.00 minimum bid price requirement. The stock was transferred to the Nasdaq Capital Market effective July 2, 2026.
-
Financial Results
Net loss for the six months ended June 30, 2026 was $16.1 million, down from $40.8 million a year earlier. Cash, cash equivalents and restricted cash totaled $59.6 million, providing a runway of at least 12 months.
-
Merger Update
The all-stock merger with Clywedog Therapeutics is expected to close in the second half of 2026. A self-tender offer of up to $27.0 million may be conducted for existing shareholders prior to the merger.
-
Clinical Progress
Enrollment was completed in all cohorts of the multiple ascending dose portion of the Phase 1 AVALON trial for VTP-1000 in celiac disease.
Analysis · BRNS · Life Sciences
Barinthus Biotherapeutics reported a net loss of $16.1 million for the first half of 2026, a sharp improvement from $40.8 million a year earlier, as cost cuts took hold. Cash stood at $59.6 million, enough to fund operations for at least 12 months on a standalone basis. The company also disclosed it received a Nasdaq delisting extension until December 28, 2026, and its shares moved to the Nasdaq Capital Market. The pending reverse merger with Clywedog Therapeutics remains on track to close in the second half of 2026, with a potential $27 million self-tender offer for existing shareholders. Enrollment in the Phase 1 AVALON trial for celiac disease candidate VTP-1000 was completed, a key clinical milestone.
At the time of this filing, BRNS was trading at $0.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.3M. The 52-week trading range was $0.51 to $1.83. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.